BMD at the lumbar spine, total hip, and femoral neck
Compared with the placebo group, significant increases from baseline in BMD were observed at the lumbar spine across all SHR-1222 dosing groups 2 months after the first administration, which continued to rise throughout the subsequent treatment (Mean (SD) percentage changes from baseline in bone mineral density (BMD). 